Vivotif Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing incidence of typhoid in endemic regions, expansion of international travel to high-risk areas, government-led immunization initiatives, availability of oral vaccine formulations, rising public health awareness.

The growth in the forecast period can be attributed to increasing investments in preventive healthcare, rising travel vaccination demand, expansion of pediatric immunization coverage, growing focus on antimicrobial resistance prevention, improved access to vaccines in emerging markets. Major trends in the forecast period include increasing adoption of oral vaccination programs, rising demand for travel-related vaccines, growing focus on preventive infectious disease management, expansion of cold-chain optimized vaccine distribution, enhanced awareness of typhoid prevention.

The rising incidence of typhoid fever is expected to drive the growth of the Vivotif market in the coming years. Typhoid fever is a bacterial infection caused by Salmonella Typhi, which spreads through contaminated food or water and leads to symptoms such as fever, abdominal pain, and fatigue. The increasing incidence of typhoid fever is attributed to poor sanitation, limited access to clean water, and growing antibiotic resistance, particularly in low-income regions. Vivotif helps lower typhoid fever incidence by offering a preventive oral vaccine against Salmonella Typhi, especially in areas with inadequate sanitation. For example, in August 2024, according to reports published by GOV.UK, a UK-based government platform, approximately 645 cases of typhoid fever were reported in England, Wales, and Northern Ireland in 2023, up from 470 cases in 2022, indicating a year-over-year increase in disease incidence. Thus, the rising incidence of typhoid fever is propelling the growth of the Vivotif market.

The increase in healthcare spending is expected to drive the growth of the Vivotif market going forward. Healthcare spending refers to the total amount spent on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, aimed at maintaining or improving the health and well-being of individuals and populations. Healthcare spending is influenced by factors such as an aging population, advancements in medical technology, rising prevalence of chronic diseases, and increased demand for healthcare services. Healthcare expenditure supports Vivotif by providing funds for the research, production, and distribution of the oral typhoid vaccine, ensuring its availability and accessibility to populations at risk of typhoid fever, thereby contributing to public health initiatives and disease prevention in regions with high incidence rates. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK grew by 5.6% compared with 0.9% growth in 2022. The UK healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. Therefore, the increase in healthcare spending is supporting the growth of the Vivotif market.

In May 2023, Bavarian Nordic A/S, a Denmark-based pharmaceutical company, acquired Emergent BioSolutions for $0.274 billion. Through this acquisition, Bavarian Nordic enhances its presence in the vaccine market by incorporating Vivotif (for typhoid fever), Vaxchora (for cholera), and a Phase 3 Chikungunya vaccine. Emergent BioSolutions is a US-based life sciences company that develops Vivotif.

Major companies operating in the vivotif market are Bavarian Nordic A/S.

Asia-Pacific was the largest region in the vivotif market in 2025. The regions covered in the vivotif market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vivotif market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the vivotif market by increasing costs associated with imported pharmaceutical raw materials, specialized manufacturing inputs, packaging components, and cold-chain logistics equipment used in oral vaccine production and distribution. Regions dependent on cross-border pharmaceutical supply chains, particularly Europe and Asia-Pacific, are most affected due to higher import duties on biologics and medical-grade materials. These tariffs can elevate vaccine procurement costs for healthcare providers and public health programs. However, they are also encouraging localized vaccine manufacturing, regional fill-and-finish facilities, and stronger domestic supply chains, supporting long-term market resilience and supply security.

The vivotif market research report is one of a series of new reports that provides vivotif market statistics, including vivotif industry global market size, regional shares, competitors with a vivotif market share, detailed vivotif market segments, market trends and opportunities, and any further data you may need to thrive in the vivotif industry. This vivotif market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vivotif is an oral vaccine used to prevent typhoid fever, a potentially serious illness caused by the bacterium Salmonella typhi. It is approved for administration in adults and children older than 6 years. It is recommended for individuals at higher risk, including travelers to regions where typhoid is common, people with close contact with S. typhi carriers, and microbiology laboratory workers who frequently handle S. typhi.

The primary clinical use of Vivotif is for typhoid, along with other indications. Typhoid is a bacterial infection mainly caused by Salmonella Typhi, which spreads through contaminated food or water. These are available through multiple distribution channels, including direct sales, online pharmacies, and retail pharmacies, and are utilized by various end-users such as adults and children.

The vivotif market consists of sales of oral typhoid vaccines and injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.